Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-2)

In this article we will discuss Durvalumab (Warnings-2)

In this article, we will discuss Durvalumab (Warnings-2). So, let’s get started.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a
PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during
treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.